pyrroles has been researched along with Adverse Drug Event in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (25.53) | 29.6817 |
| 2010's | 26 (55.32) | 24.3611 |
| 2020's | 8 (17.02) | 2.80 |
| Authors | Studies |
|---|---|
| Conway, C; Howell, BA; Siler, SQ; Watkins, PB; Woodhead, JL | 1 |
| Iihara, H; Ishida, M; Kawazoe, H; Kumada, K; Naito, J; Nonaka, Y; Okura, H; Sakai, H; Sano, M; Shimizu, M; Suzuki, A; Tsuchiya, M; Watanabe, D | 1 |
| Dong, G; Kjærgaard, NA; Sessa, M; Shakibfar, S | 1 |
| Armuzzi, A; Bressler, B; Chan, G; Colombel, JF; Danese, S; Lawendy, N; Lindsay, JO; Maller, E; Marren, A; Marshall, JK; Panés, J; Salese, L; Sandborn, WJ; Sands, BE; Su, C; Tsilkos, K; Zhang, H | 1 |
| Howell, BA; Pellegrini, L; Shoda, LKM; Woodhead, JL | 1 |
| Ailani, J; Butler, M; Finnegan, M; Hutchinson, S; Knievel, K; Lipton, RB; Lu, K; Severt, L; Trugman, JM; Yu, SY | 1 |
| Abou-Alfa, GK; Al-Rajabi, R; Borad, MJ; Catenacci, DV; Dotan, E; Féliz, L; Gallinson, D; Hollebecque, A; Ji, T; Lihou, CF; Melisi, D; Murphy, AG; Oh, DY; Paulson, AS; Sahai, V; Vaccaro, G; Van Cutsem, E; Vogel, A; Zhen, H | 1 |
| Fu, PP; He, Y; Lin, G; Ma, J; Song, Z | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 1 |
| Dong, SQ; Singh, TP; Wang, HL; Wei, X; Yao, H | 1 |
| Bakos, N; Bissonnette, R; Gardner, AC; Harper, MK; Korman, NJ; Ports, WC; Tallman, A; Tan, H; Tsai, TF; Valdez, H; Valenzuela, F | 1 |
| Castro-Poceiro, J; Fernández-Clotet, A; Panés, J | 1 |
| Prado, CM | 1 |
| Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J | 1 |
| Bae, WK; Kim, HR; Kim, HY; Kim, KH; Lee, HJ; Lee, S; Lim, HY; Rha, SY; Sun, JM | 1 |
| Ara, M; Pastushenko, E | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Hunter, ML; Mahvan, TD; Mlodinow, SG; Onysko, MK; Vandiver, JW | 1 |
| Chau, NM; Choudhury, Y; Chowbay, B; Chu, YH; Kanesvaran, R; Koh, V; Lai, J; Li, H; Ng, QS; Phyo, WM; Tan, HS; Tan, MH; Tan, PH; Toh, CK | 1 |
| Bananis, E; Burmester, G; Charles-Schoeman, C; Fleischmann, R; Hendrikx, T; Kwok, K; Nash, P; Soma, K; Zerbini, CA | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Bu, P; Yang, Y | 1 |
| Alvarez-Moreno, C; Cardiel, MH; Castañeda, OM; Castelli, G; Citera, G; García, EG; Jaller, JJ; Kwok, K; Mysler, E; Ponce de Leon, D; Radominski, SC; Rillo, O; Rojo, R; Romero, FJ; Salinas, A | 1 |
| Agnew-Blais, J; Choudhry, NK; Parker, RM; Shekelle, P; Shrank, WH; Wolf, MS | 1 |
| Jewells, V; Markovic-Plese, S; Speer, D | 1 |
| Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
| Baak-Pablo, RF; Boven, E; Eechoute, K; Gelderblom, H; Guchelaar, HJ; Haanen, JB; Mathijssen, RH; Reyners, AK; van der Straaten, T; van der Veldt, AA; van Erp, NP; Wessels, JA | 1 |
| Escudier, B; Gore, M; Mickisch, G; Nuijten, M; Procopio, G; Walzer, S | 1 |
| Porta, C | 1 |
| Charbonneau, C; Sandin, R | 1 |
| Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS | 1 |
| Budde, K; Glander, P; Mashreghi, MF; Matz, M; Naik, M; Neumayer, HH | 1 |
| Agaoglu, F; Basaran, M; Bavbek, S; Darendeliler, E; Ekenel, M; Ozcan, F; Sen, F; Tunc, HM; Yildiz, I | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
| Antón-Aparicio, L; Aparicio-Gallego, G; Blanco, M; Figueroa, A; García-Campelo, R; Grande-Pulido, E; Valladares-Ayerbes, M | 1 |
| Becker, ML; Elens, LL; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Klunk, L; Li, Z; Orlandi, C; Prakash, C | 1 |
| Abouelkhair, KM; Bayer, AM; Elmasri, OA; Ibrahim, EM; Kazkaz, GA | 1 |
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Guthrie, RM | 1 |
| McHugh, A | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Hanson, ML; Kelly, SE; Richards, SM | 1 |
| Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Corre, KA; Spielberg, TE | 1 |
13 review(s) available for pyrroles and Adverse Drug Event
| Article | Year |
|---|---|
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Piperidines; Pyridines; Pyrroles | 2023 |
Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Topics: Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2017 |
Tofacitinib for the treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Drug-Related Side Effects and Adverse Reactions; Expert Testimony; Humans; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Signal Transduction; STAT Transcription Factors; Treatment Outcome | 2018 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies.
Topics: Cardiotonic Agents; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Humans; Indoles; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2016 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Topics: Calcineurin Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sirolimus; Tacrolimus; Treatment Outcome | 2011 |
New insights into molecular mechanisms of sunitinib-associated side effects.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Models, Biological; Pigmentation Disorders; Pyrroles; Signal Transduction; Sunitinib | 2011 |
Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.
Topics: Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2013 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
8 trial(s) available for pyrroles and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Topics: Adult; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2020 |
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Calcitonin Gene-Related Peptide Receptor Antagonists; Chemical and Drug Induced Liver Injury; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Migraine Disorders; Pyridines; Pyrroles | 2020 |
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Topics: Adult; Aged; Cholangiocarcinoma; Drug-Related Side Effects and Adverse Reactions; Female; Fibroblast Growth Factors; Humans; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor | 2020 |
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
26 other study(ies) available for pyrroles and Adverse Drug Event
| Article | Year |
|---|---|
Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
Topics: Azepines; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Chemical and Drug Induced Liver Injury; Computer Simulation; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Nephritis, Interstitial; Pyrroles; Sulfonamides | 2022 |
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Pyrroles; Tolvaptan | 2020 |
Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids.
Topics: Activation, Metabolic; Animals; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Liver; Lung; Monocrotaline; Proteins; Pyrroles; Pyrrolizidine Alkaloids; Rats | 2020 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States | 2014 |
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Registries; Renal Insufficiency; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2014 |
Statin adverse effects: sorting out the evidence.
Topics: Atorvastatin; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Outcome Assessment, Health Care; Practice Guidelines as Topic; Pyrroles; Rhabdomyolysis; Risk Adjustment; Ubiquinone; Vitamins | 2014 |
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Pyrroles; Singapore; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Janus Kinase Inhibitors; Latin America; Long Term Adverse Effects; Male; Middle Aged; Patient Safety; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Variability in pharmacy interpretations of physician prescriptions.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Bone Density Conservation Agents; Comprehension; Contraindications; Drug Information Services; Drug Labeling; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Education, Pharmacy; Educational Status; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibuprofen; Patient Education as Topic; Pharmaceutical Preparations; Pharmacies; Professional Competence; Pyrroles; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health Services; Writing | 2009 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Central Nervous System; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Heptanoic Acids; Humans; Iatrogenic Disease; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pyrroles; Risk Assessment | 2009 |
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Indoles; Leukopenia; Male; Middle Aged; Mucositis; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Risk Factors; Sunitinib; Young Adult | 2009 |
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; France; Gastrointestinal Diseases; Germany; Health Care Costs; Hematologic Diseases; Hospital Costs; Hospitalization; Humans; Hypertension; Indoles; Interferon alpha-2; Interferon-alpha; Italy; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom; Venous Thrombosis | 2010 |
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib | 2010 |
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Pyrroles; Recombinant Proteins; Sunitinib; United Kingdom | 2010 |
[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
Topics: Atorvastatin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pharmacokinetics; Platelet Aggregation Inhibitors; Precision Medicine; Pyrroles; Ticlopidine | 2010 |
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Survival Analysis; Turkey | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Haplotypes; Heptanoic Acids; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Simvastatin | 2013 |
Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
Topics: Absorption; Adolescent; Adult; Animals; Area Under Curve; Benzamides; Carbon Radioisotopes; Case-Control Studies; Chromatography, High Pressure Liquid; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Inactivation, Metabolic; Male; Metabolome; Middle Aged; Pyrroles; Rats; Rats, Sprague-Dawley; Young Adult | 2012 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Fake drugs: a problem for all.
Topics: Atorvastatin; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Fraud; Heptanoic Acids; Humans; Pyrroles | 2006 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Environmental Monitoring; Fluoxetine; Heptanoic Acids; Lethal Dose 50; Lovastatin; Pyrroles; Sertraline; Water Pollutants, Chemical; Xenobiotics; Zooplankton | 2008 |
Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
Topics: Algorithms; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Drug Information Services; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Evaluation Studies as Topic; Humans; Physician's Role; Product Surveillance, Postmarketing; Pyrroles; Role; Tolmetin; United States; United States Food and Drug Administration | 1988 |